A South of France based company has developed an Innovative automatic programmable syringe preventing filer injection in blood vessels and is looking for manufacturers & distributors.

Summary

Profile type	Company's country	POD reference
Technology offer	**France**	**TOFR20230914018**
Profile status	**Type of partnership**	**Targeted countries**
PUBLISHED	**Commercial agreement with technical assistance** **Investment agreement**	**• World**
Contact Person	**Term of validity**	**Last update**
Rita ELSTE - TOMSONE	**14 Sep 2023** **13 Sep 2024**	**14 Sep 2023**

General Information

Short summary

French company, specializing in development of injectable drug delivery technologies, has developed an innovative automatic and programmable device syringe to avoid post-injection complications in Aesthetics Medicine, Rheumatology, Phlebology and other medical branches that require areas that require the injection of 2 products simultaneously or consecutively (3,5 million dermal filler procedures per year).
The company is looking for licensing, co-development and any other form of partner seeked

Full description

The company based in South of France has been launched in 2019. Their scientific board is composed by 4 international KOL from France, the USA and Israel.

Through the last decade, injection of dermal fillers became a prevalent procedure in the cosmetic dermatology practice. Hyaluronic acid (HA) fillers are the most common type (about 80%) of all injectable soft tissue fillers with continuous increase of 5-10% every year.

With the exploding usage of dermal fillers, also the number of complications continuously increase.These serious complications are the consequence of the blindly injection of the filler into an artery which produces immediate

ischaemia and sometimes irreversible necrosis of cutaneous and subcutaneous tissues.

Based on an innovative Fluid Mechanics Mathematic Model, Syrengy have developed an innovative syringe allowing safe and reliable injection to avoid product injection into blood veins and vessels.

The device is made up of 2 compartments suitable for standard and pre-filled syringest. The upward and downward movement of the plungers is controlled by a microprocessor.

The device automatically starts to aspirate a non-viscous saline solution through the first syringe. If no blood is seen in the syringe, the doctor can safely inject the product from the second syringe.

Advantages and innovations

Automatic control and optimization of pressure/force combinations.

Use of standard syringe.

No needle/cannular size dependency

Control and visualisation of the aspiration/injection parameters : material volume injected, speed.

Ability to combine 2 different materials simultaneously or sequentially.

Potential use for additional medical applications: Vascular surgery, Vein sclerotherapy, Pain clinic, Intradural injections

Technical specification or expertise sought

Stage of development

Available for demonstration

IPR Status

IPR granted

Sustainable Development goals

• Not relevant

Partner Sought

Expected role of the partner

The company is looking for 2 types of collaboration : patent licensing or transfer such as:
- Companies manufacturing disposable medical devices injector syringes, needles, who want to add the offered products to their portfolio to sell to pharmaceutical companies producing
- Business companies specialized in the field - under a services agreement.

Type of partner:
- Syringe manufacturer
- Medical device manufacturer
- Pharmaceutical companies (Medical Aesthetics, Rheumatology, Phlebology …)

Type of partnership

Commercial agreement with technical assistance

Investment agreement

Type and size of the partner

- **SME 50 - 249**
- **Big company**

Dissemination

Technology keywords

- **06001017 - Surgery**
- **06001006 - Human vaccines**
- **06001021 - Single Use Products and Consumer Goods**

Market keywords

- **05004004 - Medical instruments**
- **05005019 - 'Surgery and Anaesthesiology**
- **05004006 - Surgical instrumentation and equipment**
- **05007001 - Disposable products**

Targeted countries

- **World**

Sector groups involved

- **Health**

Media

Images

Image1.png

PDF documents

Deck Syrengy July 2023 - anonymisé.pdf

1